dementia glp-1 Can agonists and SGLT-2 inhibitors decrease risk?, Two recent JAMA Neurology studies examined the association., 🔗 Read more via our link in bio The Medicine Maker | GLP-1s

Among GLP-1s, semaglutide demonstrated the strongest benefits, including ~ 40% lower depression-related outcomes and a 42% reduction in psychiatric hospitalization

Meanwhile, usage fell considerably during the warmer months

If you miss a dose of Repatha, you should take it as soon as you remember

Neurological and Cognitive Considerations Some findings suggest that Tesamorelin, as a GHRH analog, may influence brain chemistry by altering levels of neurotransmitters such as GABA and myo-inositol

State-by-state telehealth prescribing laws govern where the company can see patients

Integrating transcriptomics and network pharmacology to reveal the mechanisms of total Rhizoma coptidis alkaloids against nonalcoholic steatohepatitis